Return on Assets (ROA): Staar Surgical's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.99%, the company showcases efficient use of ...
STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued a Shareholder Letter on ...
Staar Surgical saw a net loss of $18.3 million, or 37¢ EPS, for the fourth quarter, causing its co-CEOs to address the poor performance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results